Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

A study reveals that venetoclax consolidation after BTKi therapy is effective for chronic lymphocytic leukemia, offering ...

The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for decitabine/cedazuridine plus venetoclax to treat adults with newly diagnosed acute myeloid leukemia ...

At a lymphoma conference, experts sparred about treatment options, while an outside expert highlighted the value of each approach.

A panelist discusses how the ASCERTAIN-V study demonstrated that an all-oral combination of decitabine-cedazuridine plus ...

Data suggest that “venetoclax usage should be avoided in the general relapsed or refractory multiple myeloma population,” the researchers wrote.

Venetoclax shows potential in pediatric relapsed/refractory AML/MDS, with a 41.6% overall response rate and 33% complete response rate in a single-center study.

CALQUENCE plus venetoclax with obinutuzumab reduced the risk of disease progression or death by 58% versus standard of care in this setting. CALQUENCE plus venetoclax poised to become first all ...

The VERONA trial evaluated the safety and efficacy of venetoclax with azacitidine in treatment-naïve adults with higher-risk MDS.

AbbVie, in collaboration with Roche-Genentech, is conducting a Phase 3 clinical study titled ‘Multicenter, Phase 3 Study of Venetoclax and Azacitidine as Maintenance Therapy for Patients With ...

By Denny Jacob. AbbVie said its Phase 3 trial evaluating venetoclax in combination with azacitidine to treat higher-risk myelodysplastic syndrome didn't meet the primary endpoint of overall survival.